These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 23685570

  • 1. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
    Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT.
    Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
    [Abstract] [Full Text] [Related]

  • 2. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
    Cilibrizzi A, Quinn MT, Kirpotina LN, Schepetkin IA, Holderness J, Ye RD, Rabiet MJ, Biancalani C, Cesari N, Graziano A, Vergelli C, Pieretti S, Dal Piaz V, Giovannoni MP.
    J Med Chem; 2009 Aug 27; 52(16):5044-57. PubMed ID: 19639995
    [Abstract] [Full Text] [Related]

  • 3. Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.
    Cilibrizzi A, Schepetkin IA, Bartolucci G, Crocetti L, Dal Piaz V, Giovannoni MP, Graziano A, Kirpotina LN, Quinn MT, Vergelli C.
    Bioorg Med Chem; 2012 Jun 15; 20(12):3781-92. PubMed ID: 22607879
    [Abstract] [Full Text] [Related]

  • 4. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
    Vergelli C, Schepetkin IA, Ciciani G, Cilibrizzi A, Crocetti L, Giovannoni MP, Guerrini G, Iacovone A, Kirpotina LN, Ye RD, Quinn MT.
    Drug Dev Res; 2017 Feb 15; 78(1):49-62. PubMed ID: 27859446
    [Abstract] [Full Text] [Related]

  • 5. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
    Kirpotina LN, Schepetkin IA, Khlebnikov AI, Ruban OI, Ge Y, Ye RD, Kominsky DJ, Quinn MT.
    Biochem Pharmacol; 2017 Oct 15; 142():120-132. PubMed ID: 28690139
    [Abstract] [Full Text] [Related]

  • 6. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
    Schepetkin IA, Kirpotina LN, Khlebnikov AI, Leopoldo M, Lucente E, Lacivita E, De Giorgio P, Quinn MT.
    Biochem Pharmacol; 2013 Feb 01; 85(3):404-16. PubMed ID: 23219934
    [Abstract] [Full Text] [Related]

  • 7. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
    Crocetti L, Vergelli C, Guerrini G, Cantini N, Kirpotina LN, Schepetkin IA, Quinn MT, Parisio C, Di Cesare Mannelli L, Ghelardini C, Giovannoni MP.
    Bioorg Chem; 2020 Jul 01; 100():103880. PubMed ID: 32388428
    [Abstract] [Full Text] [Related]

  • 8. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.
    Vergelli C, Schepetkin IA, Ciciani G, Cilibrizzi A, Crocetti L, Giovannoni MP, Guerrini G, Iacovone A, Kirpotina LN, Khlebnikov AI, Ye RD, Quinn MT.
    Bioorg Med Chem; 2016 Jun 01; 24(11):2530-2543. PubMed ID: 27134116
    [Abstract] [Full Text] [Related]

  • 9. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
    Schepetkin IA, Kirpotina LN, Khlebnikov AI, Jutila MA, Quinn MT.
    Mol Pharmacol; 2011 Jan 01; 79(1):77-90. PubMed ID: 20943772
    [Abstract] [Full Text] [Related]

  • 10. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
    Kirpotina LN, Khlebnikov AI, Schepetkin IA, Ye RD, Rabiet MJ, Jutila MA, Quinn MT.
    Mol Pharmacol; 2010 Feb 01; 77(2):159-70. PubMed ID: 19903830
    [Abstract] [Full Text] [Related]

  • 11. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
    Schepetkin IA, Kirpotina LN, Khlebnikov AI, Cheng N, Ye RD, Quinn MT.
    Biochem Pharmacol; 2014 Dec 15; 92(4):627-41. PubMed ID: 25450672
    [Abstract] [Full Text] [Related]

  • 12. Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.
    Vergelli C, Khlebnikov AI, Crocetti L, Guerrini G, Cantini N, Kirpotina LN, Schepetkin IA, Cilibrizzi A, Quinn MT, Rossi P, Paoli P, Giovannoni MP.
    Chem Biol Drug Des; 2021 Oct 15; 98(4):582-603. PubMed ID: 34148303
    [Abstract] [Full Text] [Related]

  • 13. Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.
    Khlebnikov AI, Schepetkin IA, Kirpotina LN, Brive L, Dahlgren C, Jutila MA, Quinn MT.
    J Mol Model; 2012 Jun 15; 18(6):2831-43. PubMed ID: 22127612
    [Abstract] [Full Text] [Related]

  • 14. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
    Maaty WS, Lord CI, Gripentrog JM, Riesselman M, Keren-Aviram G, Liu T, Dratz EA, Bothner B, Jesaitis AJ.
    J Biol Chem; 2013 Sep 20; 288(38):27042-27058. PubMed ID: 23873933
    [Abstract] [Full Text] [Related]

  • 15. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
    Kretschmer D, Rautenberg M, Linke D, Peschel A.
    J Leukoc Biol; 2015 Apr 20; 97(4):689-97. PubMed ID: 25724390
    [Abstract] [Full Text] [Related]

  • 16. Functional selective FPR1 signaling in favor of an activation of the neutrophil superoxide generating NOX2 complex.
    Lind S, Dahlgren C, Holmdahl R, Olofsson P, Forsman H.
    J Leukoc Biol; 2021 Jun 20; 109(6):1105-1120. PubMed ID: 33040403
    [Abstract] [Full Text] [Related]

  • 17. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
    Lind S, Sundqvist M, Holmdahl R, Dahlgren C, Forsman H, Olofsson P.
    Biochem Pharmacol; 2019 Aug 20; 166():163-173. PubMed ID: 31085160
    [Abstract] [Full Text] [Related]

  • 18. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
    Schepetkin IA, Khlebnikov AI, Giovannoni MP, Kirpotina LN, Cilibrizzi A, Quinn MT.
    Curr Med Chem; 2014 Aug 20; 21(13):1478-504. PubMed ID: 24350845
    [Abstract] [Full Text] [Related]

  • 19. Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.
    Khlebnikov AI, Schepetkin IA, Quinn MT.
    Eur J Med Chem; 2010 Nov 20; 45(11):5406-19. PubMed ID: 20870313
    [Abstract] [Full Text] [Related]

  • 20. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.
    Prevete N, Liotti F, Visciano C, Marone G, Melillo RM, de Paulis A.
    Oncogene; 2015 Jul 20; 34(29):3826-38. PubMed ID: 25263443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.